Ocular Melanoma Treatment Options
Once a diagnosis of ocular melanoma is made, choice of treatment depends on the location, site of origin within the eye, size of the tumor, as well as patient age, overall health, visual potential and status of the unaffected eye. Because OM is resistant to conventional systemic therapies, early diagnosis and treatment is essential. If the melanoma has metastasized, or spread, it can be more difficult to treat. Find an ocular melanoma specialist to help you with your treatment decision.
Treatment of Primary Ocular Melanoma
The primary goals of treating the eye tumor include preventing metastasis, sparing the eye and preserving vision. View our Questions to Ask Your Doctor if you have primary disease.
For most small and medium size tumors, radiation is the recommended treatment. There are no studies showing that one form of radiation is better than another form.
- Plaque Radiotherapy (aka Brachytherapy) – This is the most common therapy for posterior ocular melanomas (choroidal and ciliary body). It consists of suturing a small, metallic object, containing radioactive material, to the wall of the eye adjacent to the tumor. Once the tumor has received sufficient radiation to destroy the tumor, the plaque is again removed surgically. This has become the standard of care for most melanoma patients with small or medium size tumors. Depending on the radiation laws of the state in which treatment is given, a patient may be required to stay in the hospital for the entire length of treatment. However, some states allow patients to be at home for the treatment.
- Proton Beam Radiotherapy – Charged particle therapy that delivers a focused dose of radiation to the targeted area while surrounding normal tissue receives minimal radiation. Small tantalum rings are surgically placed around the edges of the tumor to direct the radiation beams.
- Stereotactic Radiotherapy – Provides radioactive dose to tumor in small fractions that convene on the target tumor such that the tumor receives the total dose, while surrounding tissues receive a smaller dose. To date, there is not widespread use of this treatment for ocular melanoma and more research is needed to understand its specific role.
Types of Surgery:
In some cases, the recommended treatment for ocular melanoma is surgical removal of the tumor. Surgery is often recommended for tumors of large size and for iris melanomas in particular. Also, surgery may be recommended for recurrent disease, after initial radiation treatment.
- Enucleation – Removal of the eye is sometimes necessary in cases involving large tumors. Following removal of the eye, an artificial eye can be placed in the socket.
- Iridectomy – Removal of part of the iris where the tumor is present.
- Iridocyclectomy – Removal of part of the iris as well as the adjacent ciliary body where the tumor is present.
- Trans-Sclera Local Resection – The tumor is removed through an opening in the wall of the eye. This is often used when the tumor is large. A radioactive plaque is usually placed over the treated area to reduce tumor recurrence.
- Trans-Retinal Endoresection – The tumor is removed through a hole in the retina. This can be useful when the tumor is located close to the optic nerve. Laser treatment is given to prevent tumor recurrence.
Additional Treatments that May Be Recommended:
- Transpupillary Thermotherapy – Laser treatment that involves heating the tumor using an infrared laser beam. The treatment lasts about half an hour and is delivered under local anesthesia on an outpatient basis. This treatment is suitable for small tumors, when there is uncertainty as to whether the lesion is a benign nevus or a malignant melanoma. It is also useful for melanomas that are leaking excessive amounts of fluid and fat after previous radiotherapy.
- Intraocular Injections – Intraocular injections, which are quite painless, are given under local anesthetic. These may include steroids for inflammation and or anti-angiogenic factors, which shrink blood vessels.
Treatment of Metastatic Ocular Melanoma
Once OM has spread beyond the eye, it is considered to be metastatic. Approximately half of OM patients will develop metastatic disease. When OM metastasizes, it spreads to the liver nearly 90% of the time. In general, prognosis is poor after the tumor has metastasized. Without treatment, the median survival time is between 2-8 months. Note that this is only a median overall survival and does not necessarily indicate your prognosis. Although there are currently no approved treatments for metastatic OM, there are several palliative treatments, as well as new clinical trials, offered in the US and Europe. Find an ocular melanoma specialist who can discuss all of the treatment options with you, including clinical trials. View our Questions to Ask Your Doctor if you have metastatic disease.
Liver Directed Treatments:
- Resection - Surgical removal of metastatic tumor. Only about 9% of patients are eligible for resection because of the presence of multiple tumors in the liver at the time of diagnosis
- Ablation - Can be done percutaneously (through the skin) or surgically. Ablation involves inserting small probes into tumors and heating (i.e. radio frequency ablation, microwave ablation) or freezing (cryoablation) the tumors to kill them.
- Radiation - Targeted radiation can be used to treat liver disease. This includes treatments such as stereotactic radiosurgery (Gamma Knife and Cyber Knife), that can be used to target specific tumors while sparing normal tissue.
Transarterial Catheter-Directed Liver Therapies
A particular substance is infused into the liver through a catheter that is inserted into an artery. Unlike ablation, these therapies treat an entire side of the liver or can treat both sides at once.
- Hepatic Arterial Chemoinfusion (HAI): Infusion of chemotherapy into the liver through a specialized infusion system in which a catheter is placed into the hepatic artery to directly and continuously deliver the chemotherapy to the liver. This direct infusion minimizes the side-effects of the chemotherapy and allows high doses to be administered.
- Transarterial Chemoembolization (TACE): Infusion of chemotherapy into the liver through the hepatic artery. Unlike HAI, this procedure results in episodic doses of chemotherapy. Also, unlike HAI, TACE exerts its actions in two ways: 1) delivering chemotherapy to the tumors, and 2) the procedure results in intermittent decrease of blood to tumor tissue. The goal is tumor death.
- Immunoembolization: Similar to TACE, but infusion of immunotherapy agent into the liver (e.g. GMCSF) rather than a chemotherapeutic agent.
- Radioembolization: Similar to TACE, but infusion of radioactive beads into the liver. The radioactive beads lodge in the small blood vessels around the tumor and radiate the tumor. The goal is tumor death. Two examples of this treatment include Sirspheres and Theraspheres.
- Isolated Hepatic Perfusion (IHP): A different type of procedure to deliver high doses of chemotherapy to the liver. In IHP, a catheter is placed into the artery that provides blood to the liver; another catheter is placed into the vein that takes blood away from the liver. This temporarily separates the liver’s blood supply from blood circulating through the rest of the body and allows high doses of chemotherapy to be directed to the liver only. When it is done percutaneously, or in a less invasive method, it is referred to as Percutaneous Hepatic Perfusion (PHP).
Other Local Interventions that May be Recommended:
- Radiation: Described above, radiation can be used to treat other areas of the body including lung, bone, and brain. Depending on the location of the tumors, regular external beam radiation therapy may be better suited than stereotactic radiosurgery. Radiation therapy can be used to treat isolated metastases or to relieve symptoms caused by a specific lesion.
- Ablation: Described above, ablation can be used in other areas of the body beyond the liver, such as lung, kidney, and soft tissue.
Although, currently, there are no approved systemic treatments for metastatic ocular melanoma, some providers recommend treatment with systemic agents, such as ipilimumab (Yervoy), that have been approved for cutaneous melanoma. Alternatively, there are ongoing clinical trials in which patients have access to systemic agents before they are approved. To learn about clinical trials, please visit the MRF's Clinical Trial Finder.
- Immunotherapy: A type of systemic therapy given in an attempt to activate a person’s own immune system so that it will destroy any melanoma cells within the body.
- Targeted therapy: A form of treatment in which drugs are developed with the goal of destroying cancer cells while leaving normal cells intact. A targeted approach allows the classification of melanoma into different “subtypes” based on the genetic profile of the tumor.
- Chemotherapy: Overall, chemotherapy has not been shown to be effective for melanoma. However, it may still be recommended in some cases.
The MRF's CURE OM initiative hosted a Scientific Meeting at the 2016 Society for Melanoma Research Congress to present the lastest news in OM immunotherapy. Following the meeting, Udai S. Kammula, M.D., F.A.C.S. of the National Cancer Institute shared his findings in a research summary. Dr. Kammula will also discuss OM immunotherapy at the 6th Annual Eyes on a Cure: Patient & Caregiver Symposium.